Literature DB >> 3973719

Radiation therapy for incompletely resected meningiomas.

A M Petty, L E Kun, G A Meyer.   

Abstract

Twelve patients with incompletely resected meningiomas were treated with postoperative radiation therapy. Nine of these patients had previously undergone incomplete surgical resection, and three had suffered one or more postoperative recurrences. The median dose of irradiation was 5490 rads in 6 weeks (range 4800 to 6080 rads). All patients were followed with serial neurological examinations and computerized tomography (CT) scans. Median follow-up period was 54 1/2 months (range 20 to 120 months); 10 of the 12 patients were followed for longer than 42 months posttreatment. Nine patients had no clinical evidence of recurrent disease after radiation therapy, and CT scans confirmed lack of progression or a gradual decrease in tumor size. Three patients had tumor recurrences; two of these lesions appeared at 70 and 112 months after irradiation as extracranial extensions beyond the margin of the irradiation field, and one has exhibited recurrence within the field at 48 months. Three patients who were treated after prior recurrences have demonstrated prolonged progression-free intervals in comparison to the intervals between recurrences prior to irradiation. No significant complications attributable to treatment have been found in any of the patients. These results are discussed in relation to previous reports of the incidence of meningioma recurrence after incomplete resection.

Entities:  

Mesh:

Year:  1985        PMID: 3973719     DOI: 10.3171/jns.1985.62.4.0502

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Extended Retrosigmoid Approach for Cerebellopontine Angle Meningiomas: Operative Technique and Results-A Series of 28 Patients.

Authors:  Jose Carlos Lynch; Celestino Pereira; Leonardo Welling; Mariangela Gonçalves; Nelci Zanon
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-18

2.  Rate of progression and severity of neuro-ophthalmologic manifestations of cavernous sinus meningiomas.

Authors:  K C Golnik; N R Miller; D M Long
Journal:  Skull Base Surg       Date:  1992

3.  Meningioma of the posterior skull base.

Authors:  M T Biggs; P A Fagan; J P Sheehy; P J Bentivoglio; B D Doust; J Tonkin
Journal:  Skull Base Surg       Date:  1991

4.  Management of petroclival meningiomas: a review of the development of current therapy.

Authors:  Adrian J Maurer; Sam Safavi-Abbasi; Ahmed A Cheema; Chad A Glenn; Michael E Sughrue
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-27

5.  Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67.

Authors:  W Roggendorf; T Schuster; J Peiffer
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

6.  Meningioma in the pediatric population.

Authors:  J E Baumgartner; J M Sorenson
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

7.  The results of radiosurgical management of 72 middle fossa meningiomas.

Authors:  V Valentino; G Schinaia; A J Raimondi
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

8.  Systematic Analysis of Outcomes for Surgical Resection and Radiotherapy in Patients with Papillary Meningioma.

Authors:  Christina Fong; Daniel T Nagasawa; Lawrance K Chung; Brittany Voth; Nicole Cremer; Kimberly Thill; Nolan Ung; Quinton Gopen; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2015-03-12

9.  The role of radiotherapy in the treatment of subtotally resected benign meningiomas.

Authors:  R Miralbell; R M Linggood; S de la Monte; K Convery; J E Munzenrider; R O Mirimanoff
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

10.  Linear accelerator-based radiosurgery in the management of skull base meningiomas.

Authors:  Chi-Cheng Chuang; Chen-Nen Chang; Ngan-Ming Tsang; Kuo-Chen Wei; Chen-Kan Tseng; Joseph Tung-Chien Chang; Ping-Ching Pai
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.